Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16343629 | 0.99 | PARP1 (0.49) | PARP1CHEK1ACHEHRH3HRH4 | |
| SCHEMBL16343638 | 0.90 | PARP1 (0.52) | PARP1CHEK1ACHEHRH3 | |
| SCHEMBL15155147 | 0.89 | CHEK1 (0.42) | PARP1CHEK1ACHEHRH3 | |
| SCHEMBL16344703 | 0.88 | PARP1 (0.43) | PARP1CHEK1ACHEHRH3ALDH1A1 | |
| SCHEMBL15155222 | 0.86 | GRM2 (0.42) | PARP1CHEK1ACHEHRH3ALDH1A1 | |
| SCHEMBL16343850 | 0.85 | CHKA (0.41) | PARP1CHEK1ACHEALDH1A1WNT1 | |
| SCHEMBL15154942 | 0.84 | GRM2 (0.44) | PARP1CHEK1ACHEWNT1CLK2 | |
| SCHEMBL16344223 | 0.81 | IKBKE (0.42) | PARP1CHEK1ACHEHRH3WNT1 | |
| SCHEMBL16343530 | 0.79 | PARP1 (0.39) | PARP1PARP2 | |
| SCHEMBL16343566 | 0.79 | PARP1 (0.47) | PARP1HRH3CYP2D6CYP2C19PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | claimed |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | claimed |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | claimed |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2809670-B1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | PARP1 388/4885CHEK1 193/4885ACHE 3736/4885 |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | PARP1 388/4885CHEK1 193/4885ACHE 3736/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | PARP1 388/4885CHEK1 193/4885ACHE 3736/4885 |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | PARP1 388/4885CHEK1 193/4885ACHE 3736/4885 |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | PARP1 388/4885CHEK1 193/4885ACHE 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.